Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis.
Maini
R N
RN
The Kennedy Institute of Rheumatology and Imperial College School of Medicine, London.
Taylor
P C
PC
Paleolog
E
E
Charles
P
P
Ballara
S
S
Brennan
F M
FM
Feldmann
M
M
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000503:physiopathology* / Q000628:therapy*; D016207:Cytokines / Q000096:biosynthesis; D006801:Humans; D000069285:Infliximab; D009389:Neovascularization, Pathologic / Q000503:physiopathology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology* / Q000502:physiology
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D016207:Cytokines; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab